Survival and toxicity in patients with human papilloma virus‐associated oropharyngeal squamous cell cancer receiving trimodality therapy including transoral robotic surgery

Abstract

Patients with oropharyngeal cancer who undergo transoral robotic surgery (TORS) and have high‐risk features generally receive adjuvant chemoradiotherapy or trimodality therapy (TMT). The notion that TMT leads to high toxicity is largely based on studies that included human papilloma virus (HPV)‐negative cancers and/or nonrobotic surgery; we sought to describe outcomes in HPV‐associated oropharyngeal squamous cell cancer (HPV\u2009+\u2009OPSCC) undergoing TORS‐TMT.